SCD and metabolic syndrome: In humans, higher activity of SCD-1 and lower activity of elongase, as described herein for the HCD group, are associated with obesity [36], hypertriglyceridemia [37], metabolic syndrome [27,38], insulin resistance [39], and NASH [17].